Front matter (notice n° 1671845)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01610cam a2200169 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260301000525.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kamar, Nassim |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Front matter |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 96 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Due to increased use of kidneys from extended criteria donors, there is an increased early use of belatacept to avoid the nephrotoxicity of calcineurin inhibitors. A belatacept calcineurin inhibitors-free regimen is associated with an increased risk of T-cell mediated rejection and opportunistic infections, particularly cytomegalovirus (CMV) infection. To prevent CMV infection, a novel anti-viral drug, letermovir, is now available. In patients who present refractory/resistant CMV infections, it is nowadays recommended to use maribavir. However, the management of CMV infection still requires further studies. For instance, the role of anti-CMV immunoglobulins to prevent or to treat CMV infection, in association with classical anti-viral drugs, ought to be studied. The effect of belatacept on BK virus replication is controversial. There is no specific anti-viral treatment directed against BK virus. It is recommended to monitor closely BKV DNAemia and to reduce immunosuppression in case of positivity, especially in patients with high viral load or BKV-associated nephropathy |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Del Bello, Arnaud |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Néphrologie & Thérapeutique | Volume 21 | 4 | 2025-06-27 | p. 129-132 | 1769-7255 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-nephrologie-therapeutique-2025-4-page-129?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-nephrologie-therapeutique-2025-4-page-129?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux